Su1883 HER-2 Expression in the Barrett's Metaplasia-Dysplasia-Carcinoma Sequence and Potential Targeting In-Vitro With the Single Chain Antibody Fragment C6.5

Introduction null There is increasing attention on the integration of targeted agents for oesophageal adenocarcinoma (OA) therapy. The most notable example of success of oesophagogastric targeted therapy was the addition of a HER2 targeting agent in the Phase III ToGA study. However, there is limited data on the expression of HER2 in the progression from Barrett9s (BE) to OA. This study aimed to clarify expression in this sequence, and to show...